88 related articles for article (PubMed ID: 23581412)
21. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P
Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
23. CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation.
Ritt DA; Zhou M; Conrads TP; Veenstra TD; Copeland TD; Morrison DK
Curr Biol; 2007 Jan; 17(2):179-84. PubMed ID: 17174095
[TBL] [Abstract][Full Text] [Related]
24. Mithramycin A inhibits myeloid cell leukemia-1 to induce apoptosis in oral squamous cell carcinomas and tumor xenograft through activation of Bax and oligomerization.
Shin JA; Jung JY; Ryu MH; Safe S; Cho SD
Mol Pharmacol; 2013 Jan; 83(1):33-41. PubMed ID: 23019217
[TBL] [Abstract][Full Text] [Related]
25. Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines.
Stoeger SM; Cowan KH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):807-18. PubMed ID: 18661133
[TBL] [Abstract][Full Text] [Related]
26. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway.
Yu T; Wu Y; Helman JI; Wen Y; Wang C; Li L
Mol Cancer Res; 2011 Feb; 9(2):161-72. PubMed ID: 21205837
[TBL] [Abstract][Full Text] [Related]
27. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
Hamakawa H; Nakashiro K; Sumida T; Shintani S; Myers JN; Takes RP; Rinaldo A; Ferlito A
Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
[TBL] [Abstract][Full Text] [Related]
28. Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt.
Brusevold IJ; Aasrum M; Bryne M; Christoffersen T
J Oral Pathol Med; 2012 Aug; 41(7):547-58. PubMed ID: 22413835
[TBL] [Abstract][Full Text] [Related]
29. Kinase suppressor of Ras (KSR1) modulates multiple kit-ligand-dependent mast cell functions.
Chen M; Burgin S; Staser K; He Y; Li X; Robinson M; Jiang L; Chan RJ; Ingram D; Clapp DW
Exp Hematol; 2011 Oct; 39(10):969-76. PubMed ID: 21726514
[TBL] [Abstract][Full Text] [Related]
30. Targeting l1 cell adhesion molecule using lentivirus-mediated short hairpin RNA interference reverses aggressiveness of oral squamous cell carcinoma.
Hung SC; Wu IH; Hsue SS; Liao CH; Wang HC; Chuang PH; Sung SY; Hsieh CL
Mol Pharm; 2010 Dec; 7(6):2312-23. PubMed ID: 21033655
[TBL] [Abstract][Full Text] [Related]
31. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
Arthan D; Hong SK; Park JI
Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.
Iwase M; Takaoka S; Uchida M; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M
Oral Oncol; 2008 Apr; 44(4):361-8. PubMed ID: 17689285
[TBL] [Abstract][Full Text] [Related]
33. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
Kogut MH; Genovese KJ; He H
Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
[TBL] [Abstract][Full Text] [Related]
34. The dietary phytochemical 3,3'-diindolylmethane induces G2/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NF-κB, MAPK, and p53 signaling.
Weng JR; Bai LY; Chiu CF; Wang YC; Tsai MH
Chem Biol Interact; 2012 Feb; 195(3):224-30. PubMed ID: 22290291
[TBL] [Abstract][Full Text] [Related]
35. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.
Su L; Wang Y; Xiao M; Lin Y; Yu L
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):484-91. PubMed ID: 20868995
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of the ERK/MAP kinases in oral squamous cell carcinoma.
Mishima K; Yamada E; Masui K; Shimokawara T; Takayama K; Sugimura M; Ichijima K
Mod Pathol; 1998 Sep; 11(9):886-91. PubMed ID: 9758369
[TBL] [Abstract][Full Text] [Related]
38. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
40. Praja2 suppresses the growth of gastric cancer by ubiquitylation of KSR1 and inhibiting MEK-ERK signal pathways.
Zhao Z; Zhu L; Xing Y; Zhang Z
Aging (Albany NY); 2021 Jan; 13(3):3886-3897. PubMed ID: 33461174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
